Author

F. Pujol

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:mouse· 2 Research Focus:benchmarking· 1 Approach:biophysical modeling· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Research Focus:development & morphogenesis· 1 Research Focus:differential expression· 1

Frequent Co-Authors

A.-C. Prats· 2 shared B. Garmy-Susini· 2 shared E. Lacazette· 2 shared A. Bura-Riviere· 1 shared A. Henras· 1 shared A. Lamaa· 1 shared A. Parini· 1 shared A.-C. Godet· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 33 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

A.-C. Prats

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Apelin-VEGF-C mRNA delivery as therapeutic for the treatment of secondary lymphedema

A. Lamaa, J. Creff, E. Benuzzi, F. Pujol, T. Draia-Nicolau, M. Nougue, L. Verdu, F. Morfoisse, E. Lacazette, P. Valet, B. Chaput, F. Gross, R. Gayon, P. Bouille, J. Malloizel-Delaunay, , B. Garmy-Susini

This study identifies apelin as a therapeutic molecule for secondary lymphedema, showing it enhances lymphatic function through VEGF-C and pathways involving Akt and eNOS, with a novel RNA delivery system for clinical evaluation.

bioRxiv · Jan 5, 2023 · PreprintPathology

Vasohibin1, a new IRES trans-acting factor for induction of (lymph)angiogenic factors in early hypoxia

F. Hantelys, A.-C. Godet, F. David, F. Tatin, E. Renaud-Gabardos, F. Pujol, L. Diallo, I. Ader, L. Ligat, A. Henras, Y. Sato, E. Lacazette, A. Parini, B. Garmy-Susini, A.-C. Prats

The paper identifies vasohibin1 as an IRES trans-acting factor that activates angiogenic IRESs in early hypoxia while inhibiting others in normoxia.

bioRxiv · Jul 11, 2019 · PreprintCell Biology